Brii Biosciences Limited (2137) Price & Analysis

Compare

2 Followers

2137 Stock Chart & Stats

HK$1.44

HK$0.04(3.74%)

At close: Jan 09 4:00 PM EST

HK$1.44

HK$0.04(3.74%)

Day’s Range― - ―

52-Week RangeHK$1.38 - HK$3.09

Previous CloseN/A

Volume2.92M

Average Volume (3M)6.36M

Market Cap

HK$1.12B

Enterprise Value-HK$506.24M

Total Cash (Recent Filing)HK$2.07B

Total Debt (Recent Filing)HK$7.39M

Price to Earnings (P/E)―

Beta1.51

Next Earnings

Mar 20, 2026

EPS Estimate

-0.07

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.23

Shares Outstanding734,256,530

10 Day Avg. Volume5,897,564

30 Day Avg. Volume6,360,478

Financial Highlights & Ratios

PEG Ratio>-0.01

Price to Book (P/B)0.25

Price to Sales (P/S)12.38

P/FCF Ratio-1.79

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Strong Equity And Cash ReservesThe balance sheet shows a strong equity position and substantial cash reserves, which provide a durable runway to fund R&D and operations over the next several months. This buffer reduces near-term liquidity pressure and supports continued clinical development and partnership execution.

Proprietary Technology PlatformA proprietary technology platform focused on infectious diseases and antimicrobial resistance creates sustainable competitive advantages: high technical barriers, durable IP potential, and differentiated product candidates that attract long-term partners and premium licensing opportunities.

Partnership-driven Revenue ModelA business model that monetizes partnerships via upfronts, milestones and royalties provides recurring non-dilutive funding and risk-sharing. Structurally, this reduces sole commercialization burden and can steady cash inflows during lengthy clinical timelines.

Bears Say

Consistent Negative Free Cash FlowSustained negative free cash flow and absence of operating cash flow in 2024 indicate structural cash generation weakness. Over 2-6 months this raises refinancing or dilution risks, limits discretionary spending on trials, and increases dependency on partners or capital markets.

Widening Net Loss And Negative MarginsA materially widening net loss with negative EBIT/EBITDA margins and declining revenue from 2023 to 2024 signals persistent profitability issues. Without product approvals or revenue inflections, margins remain pressured and long-term viability depends on successful clinical or commercial milestones.

Concerning Leverage HistoryHistorical negative equity and a concerning debt-to-equity profile reflect past leverage and liability build-up. This structural leverage can increase financing costs, limit strategic flexibility for partnering or M&A, and constrain investment in expensive clinical programs.

Brii Biosciences Limited News

Brii Biosciences Updates Nomination Committee Terms

Brii Biosciences Limited ( ($HK:2137) ) just unveiled an announcement. Brii Biosciences Limited has updated the terms of...

3M ago

Brii Biosciences Reports Promising Results from Phase 2 HBV Study

Brii Biosciences Limited ( ($HK:2137) ) has shared an update. Brii Biosciences Limited has announced promising 24-week post-treatment...

3M ago

Brii Biosciences’ Phase 2 Study Shows Promise in Hepatitis B Treatment

Brii Biosciences Limited ( ($HK:2137) ) just unveiled an announcement. Brii Biosciences Limited announced the publication of its...

4M ago

Brii Biosciences Grants 600,000 Share Options to Enhance Strategic Advisory Services

The latest update is out from Brii Biosciences Limited ( ($HK:2137) ). Brii Biosciences Limited announced the grant...

4M ago

Brii Biosciences Grants Share Options and RSUs to Align Employee Interests

Brii Biosciences Limited ( ($HK:2137) ) has issued an update. Brii Biosciences Limited has announced the grant of...

4M ago

Brii Biosciences Revises Fund Allocation to Boost Therapeutic Programs

An update from Brii Biosciences Limited ( ($HK:2137) ) is now available. Brii Biosciences Limited announced a supplemental...

6M ago

Brii Biosciences Advances Hepatitis B Program Amid Financial Adjustments

Brii Biosciences Limited ( ($HK:2137) ) has issued an announcement. Brii Biosciences Limited reported a decrease in cash...

6M ago

Brii Biosciences Schedules Board Meeting to Review Interim Results

Brii Biosciences Limited ( ($HK:2137) ) just unveiled an announcement. Brii Biosciences Limited announced that its board of...

7M ago

Brii Biosciences Partners with Joincare for BRII-693 Development in Greater China

Brii Biosciences Limited ( ($HK:2137) ) just unveiled an update. Brii Biosciences Limited has entered into a licensing...

8M ago

Brii Biosciences Announces AGM Results and Board Changes

Brii Biosciences Limited ( ($HK:2137) ) has shared an announcement. Brii Biosciences Limited announced the results of its...

9M ago

2137 FAQ

What was Brii Biosciences Limited’s price range in the past 12 months?

Brii Biosciences Limited lowest stock price was HK$1.38 and its highest was HK$3.09 in the past 12 months.

What is Brii Biosciences Limited’s market cap?

Brii Biosciences Limited’s market cap is HK$1.12B.

When is Brii Biosciences Limited’s upcoming earnings report date?

Brii Biosciences Limited’s upcoming earnings report date is Mar 20, 2026 which is in 25 days.

How were Brii Biosciences Limited’s earnings last quarter?

Brii Biosciences Limited released its earnings results on Aug 21, 2025. The company reported -HK$0.226 earnings per share for the quarter, beating the consensus estimate of -HK$0.305 by HK$0.079.

Is Brii Biosciences Limited overvalued?

According to Wall Street analysts Brii Biosciences Limited’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Brii Biosciences Limited pay dividends?

Brii Biosciences Limited does not currently pay dividends.

What is Brii Biosciences Limited’s EPS estimate?

Brii Biosciences Limited’s EPS estimate is -0.07.

How many shares outstanding does Brii Biosciences Limited have?

Brii Biosciences Limited has 734,256,530 shares outstanding.

What happened to Brii Biosciences Limited’s price movement after its last earnings report?

Brii Biosciences Limited reported an EPS of -HK$0.226 in its last earnings report, beating expectations of -HK$0.305. Following the earnings report the stock price went down -0.49%.

Which hedge fund is a major shareholder of Brii Biosciences Limited?

Currently, no hedge funds are holding shares in HK:2137

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Brii Biosciences Limited

Brii Biosciences Limited engages in the development of medicines for the treatment of infectious and central nervous system diseases. The company develops BRII-778 and BRII-732, which are in phase I clinical trials for the treatment of HIV patients; BRII-179 and BRII-835, which are in Phase 2 to evaluate the combination of these two HBV mechanisms for Hepatitis B; BRII-179, a recombinant protein-based HBV immunotherapeutic candidate that is in Phase 1b/2a; BRII-835, which has completed Phase-2 for patients with chronic HBV infection; and Amubarvimab/romlusevimab combination therapy for the treatment of COVID-19. It also develops BRII-296 for the treatment of PPD; BRII-297 for treatment of various depressive disorders; BRII-636, BRII-672, and BRII-693 for the treatment of multi-drug resistant/extensive drug resistant (MDR/XDR) gram-negative infections; and BRII-658 for the treatment of MDR/XDR tuberculosis and non-tuberculosis mycobacteria. The company was incorporated in 2017 and is based in Beijing, China.